By using a machine learning approach based on PLS‐DA analysis, we investigated if the improvement in adipose tissue function (eg by increase in ADPN and changes in inflammatory markers), the changes in body fat distribution and the reduction in VF, by either weight loss or a PPAR‐γ agonist (pioglitazone), could explain the improvement in liver histology in NASH. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.